• KDventures' 33%-owned portfolio company SVF Vaccines entered a research collaboration with Orexo today to explore stable powder-based mRNA vaccine formulations.
• The collaboration will test Orexo's AmorphOX technology for spray-drying lipid nanoparticle-encapsulated mRNA while preserving nanoparticle properties and mRNA activity.
• Initial studies will assess in vitro feasibility, with further development dependent on results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.